<DOC>
	<DOCNO>NCT02412371</DOCNO>
	<brief_summary>This study seek establish recommended Phase 2 dose ( RPTD ) veliparib combination concurrent Paclitaxel/Carboplatin-based chemoradiotherapy ( Phase 1 portion ) ass whether addition oral veliparib versus placebo Paclitaxel/Carboplatin-based chemoradiotherapy Paclitaxel/Carboplatin consolidation improve progression-free survival ( PFS ) subject Stage III non-small cell lung cancer ( Phase 2 portion ) .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Tolerability Veliparib Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed Veliparib Paclitaxel/Carboplatin Consolidation Subjects With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Participants Histologically cytologically confirm Stage III nonsmall cell lung cancer ( NSCLC ) . 2 . Participants randomize portion study must measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) , version 1.1 criterion . 3 . Participants must V20 ( volume lung receive 20 Gy radiotherapy accord simulation ) &lt; 35 % . 4 . Participant must Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 . 5 . Participant must adequate hematologic , renal , hepatic , lung function . 1 . Participants prior chemotherapy radiotherapy ( RT ) current NSCLC . Participants curatively treat past early stage NSCLC great 3 year ago may include . 2 . Participants prior exposure polyADPribose polymerase ( PARP ) inhibitor . 3 . Participants know hypersensitivity carboplatin , paclitaxel , formulation contain polyethoxylated castor oil ( Cremophor ) . 4 . Participants prior mediastinal thoracic radiotherapy . Prior tangential RT prior breast cancer acceptable . 5 . Participants major surgery 4 week prior randomization ( Videoassisted thoracoscopic surgery ( VATS ) and/or mediastinoscopy consider major surgery ) . 6 . Participants previous concurrent malignancy except treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient receive potentially curative treatment diseasefree 3 year consider cure investigator diseasefree less 3 year . 7 . Participant pregnant lactating . 8 . Participant sensory peripheral neuropathy â‰¥ Grade 2 baseline , unable swallow medication , participant prior history seizure within prior 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>previously untreated</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>ABT-888</keyword>
	<keyword>stage III</keyword>
	<keyword>first line</keyword>
	<keyword>carboplatin</keyword>
	<keyword>veliparib</keyword>
	<keyword>non-small cell lung cancer</keyword>
</DOC>